文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

机器人对比开放胰十二指肠切除术(PORTAL):多中心、单盲、3期、非劣效随机对照试验

Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial.
PubMed 文献 · BMJ · 2026-07-01
一句话结论在高容量中心由认证外科医生实施时,机器人胰十二指肠切除术在术后功能恢复时间上非劣于开放手术,且不增加并发症负担。

PORTAL试验在中国7家高容量胰腺中心纳入268例可切除胰腺或壶腹周围疾病成人,随机接受标准化机器人胰十二指肠切除术(RPD,n=142)或开放胰十二指肠切除术(OPD,n=126),均采用加速康复路径。改良意向性治疗人群254例中,RPD组术后40天内功能恢复的限制性平均事件时间为12.1天(95%CI 11.2-13.1),OPD组为16.0天(95%CI 14.5-17.5),差异-3.9天(95%CI -5.6至-2.2;P<0.001),达到非劣效。

要点

  • 在高容量中心由认证外科医生实施时,RPD术后功能恢复时间非劣于OPD:RMET 12.1天 vs 16.0天,差异-3.9天(95%CI -5.6至-2.2;P<0.001)。
  • RPD组Clavien-Dindo≥II级并发症发生率为23.5%(31/132),OPD组为34.4%(42/122);总体并发症31.1% vs 36.1%。
  • RPD组手术时间更长(中位300分钟 vs 270分钟,P<0.001),但术后住院更短(中位13天 vs 16天,P<0.001)。
  • RPD组90天死亡率为0.8%(1例),OPD组为2.5%(3例)。

适用人群与场景

  • 纳入:268例可切除胰腺或壶腹周围疾病的成人,来自中国7家高容量胰腺中心,随机接受RPD(n=142)或OPD(n=126)。
  • 改良意向性治疗人群:254例实际接受手术并完成随访者(RPD组132例,OPD组122例),14例未手术。
  • 排除标准:原文未提及。

诊断标准与关键阈值

  • 主要终点:术后功能恢复时间,定义为充分镇痛且无需胃肠外镇痛、经口摄入≥50%且无需静脉补液、独立活动、无活动性腹腔内感染。
  • 主要终点汇总指标:40天内限制性平均事件时间(RMET)。
  • 非劣效界值:原文未提及具体数值。

处置流程与药物剂量

  • 第一步:在具备认证外科医生和标准化路径的高容量中心,可考虑将RPD作为OPD的替代方案;实施时需考虑机构专长、手术量、机器人平台获取与维护成本以及缩短住院的潜力(原文结论)。
  • 药物剂量与具体给药方案:原文未提及。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究设计:多中心、单盲、3期、非劣效随机对照试验,中国7家三级高容量胰腺中心,2020年6月15日至2024年11月28日。
  • 主要终点:改良意向性治疗人群(254例)中,RPD组RMET为12.1天(95%CI 11.2-13.1),OPD组为16.0天(95%CI 14.5-17.5),差异-3.9天(95%CI -5.6至-2.2;P<0.001)。
  • 手术时间:RPD组中位300分钟(IQR 240-360),OPD组中位270分钟(IQR 210-300),P<0.001。
  • 术后住院时间:RPD组中位13天(IQR 11-16),OPD组中位16天(IQR 13-20),P<0.001。
  • 总体术后并发症:RPD组31.1%(41/132),OPD组36.1%(44/122)。
  • Clavien-Dindo≥II级并发症:RPD组23.5%(31/132),OPD组34.4%(42/122)。
  • 90天死亡率:RPD组0.8%(1例),OPD组2.5%(3例)。

证据类型、等级与局限

  • 证据类型:多中心、单盲、3期、非劣效随机对照试验(RCT)。
  • 证据等级或推荐强度:原文未提及。
  • 局限性:原文未明确列出;设计上为单盲、仅纳入中国高容量中心且由认证外科医生实施,结果外推需考虑机构专长与手术量。

对床旁实践的改变

  • 在高容量中心由认证外科医生实施时,RPD可作为OPD的替代方案,不增加总体并发症负担,并可能缩短术后功能恢复时间和住院时间;但总住院费用更高,实施需权衡机构专长、手术量、机器人平台获取与维护成本。
  • 不适用人群:原文未提及。
  • 常见陷阱:原文未提及。

指南或共识出处

  • 原文未提及指南或共识;试验注册号ClinicalTrials.gov NCT04400357。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To determine whether robotic pancreatoduodenectomy (RPD) is non-inferior to open pancreatoduodenectomy (OPD) in terms of postoperative functional recovery, without compromising safety or oncological quality.

DESIGN: Multicentre, single masked, phase 3, non-inferiority randomised controlled trial.

SETTING: Seven tertiary high volume pancreatic centres in China, 15 June 2020 to 28 November 2024.

PARTICIPANTS: 268 adults with resectable pancreatic or periampullary disease.

INTERVENTIONS: Participants were randomised to receive standardised RPD (n=142) or OPD (n=126), with enhanced recovery pathways.

MAIN OUTCOME MEASURES: The primary outcome was time from surgery to postoperative functional recovery, defined as adequate pain control without parenteral analgesia, ≥50% oral intake without intravenous fluids, independent mobilisation, and absence of active intra-abdominal infection. The restricted mean event time (RMET) within 40 days was a summary for time from surgery to postoperative functional recovery. Secondary outcomes included operative metrics, disease related outcomes, length of stay, postoperative morbidity, including complications of Clavien-Dindo grade II or higher (defined as complications requiring drug treatment or more intensive intervention), and hospital admission costs.

RESULTS: Overall, 254 of 268 randomly assigned participants (mean age 62 years; 172 (64.2%) men) underwent surgery, completed follow-up, and were included in the modified intention-to-treat population; 14 did not undergo surgery. In the modified intention-to-treat population, the RMET was 12.1 days (95% confidence interval (CI) 11.2 to 13.1) in the RPD group and 16.0 days (14.5 to 17.5) in the OPD group (difference -3.9 days, 95% CI -5.6 to -2.2; P<0.001). Operative time was longer in the RPD group (300 minutes (interquartile range (IQR) 240-360 minutes) versus 270 (210-300) minutes in the OPD group, P<0.001) but postoperative length of stay was shorter in the RPD group (13 (IQR 11-16) days v 16 (13-20) days, P<0.001). Overall postoperative morbidity was 31.1% (41/132) in the RPD group versus 36.1% (44/122) in the OPD group and incidence of any complications of Clavien-Dindo grade II or higher was 23.5% (31/132) versus 34.4% (42/122), respectively. 90 day mortality was 0.8% (1) in the RPD group and 2.5% (3) in the OPD group. Median total costs of hospital admission (including readmission cost) were higher in the RPD group than in the OPD group (¥130 905 (£14 369; $19 351; €16 628) (IQR ¥114 853-¥152 547) v ¥108 071 (¥92 134-¥128 035), difference ¥22 834 (95% CI ¥16 744 to ¥30 522); P<0.001).

CONCLUSIONS: In high volume centres with credentialled surgeons, RPD met the non-inferiority margin for time from surgery to postoperative functional recovery, with comparable disease related outcomes and overall burden from postoperative complications. To generate wider system level efficiency gains, the implementation of RPD should take account of institutional expertise, procedural volume, acquisition of robotic surgical platforms and maintenance costs, and the potential for shorter hospital stay.

TRIAL REGISTRATION: ClinicalTrials.gov NCT04400357.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Jin J, Qin K, Gemenetzis G, et al. Robotic versus Open Pancreatoduodenectomy (PORTAL): multicentre, single masked, phase 3, non-inferiority randomised controlled trial. BMJ. 2026. PMID: 42386316. doi:10.1136/bmj-2026-319692

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。